Phase I, First-in-human Trial in Healthy Volunteers to Examine Increasing Single and Repeated Oral Doses of TMC647055, Followed by a Repeated-dose Part in Chronic HCV-genotype 1 Infected Patients to Examine TMC647055 Given Alone or in Combination With TMC435.

Trial Profile

Phase I, First-in-human Trial in Healthy Volunteers to Examine Increasing Single and Repeated Oral Doses of TMC647055, Followed by a Repeated-dose Part in Chronic HCV-genotype 1 Infected Patients to Examine TMC647055 Given Alone or in Combination With TMC435.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2012

At a glance

  • Drugs Simeprevir; TMC 647055
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 15 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 15 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Nov 2011 Actual patient number is 72 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top